Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics
Y Kanai - Pharmacology & therapeutics, 2022 - Elsevier
Cancer cells require a massive supply of nutrients, including sugars and amino acids—the
upregulation of transporters for each nutrient contributes to meet the demand. Distinct from …
upregulation of transporters for each nutrient contributes to meet the demand. Distinct from …
The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health
SLC7A5, known as LAT1, belongs to the APC superfamily and forms a heterodimeric amino
acid transporter interacting with the glycoprotein CD98 (SLC3A2) through a conserved …
acid transporter interacting with the glycoprotein CD98 (SLC3A2) through a conserved …
Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids
S Li, W Su, H Wu, T Yuan, C Yuan, J Liu… - Nature biomedical …, 2020 - nature.com
Strategies for selectively imaging and delivering drugs to tumours typically leverage
differentially upregulated surface molecules on cancer cells. Here, we show that …
differentially upregulated surface molecules on cancer cells. Here, we show that …
Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex
R Yan, X Zhao, J Lei, Q Zhou - Nature, 2019 - nature.com
The L-type amino acid transporter 1 (LAT1; also known as SLC7A5) catalyses the cross-
membrane flux of large neutral amino acids in a sodium-and pH-independent manner …
membrane flux of large neutral amino acids in a sodium-and pH-independent manner …
[HTML][HTML] L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia
The L-type amino acid transporter (LAT) family are Na+-independent transporters, which
deliver neutral amino acids into cells. The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 …
deliver neutral amino acids into cells. The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 …
Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond
Tumor cells have an increased demand for nutrients; this demand is met by increased
availability of nutrients through vasculogenesis and by enhanced cellular entry of nutrients …
availability of nutrients through vasculogenesis and by enhanced cellular entry of nutrients …
L-Type amino acid transporter 1 as a target for drug delivery
E Puris, M Gynther, S Auriola, KM Huttunen - Pharmaceutical research, 2020 - Springer
Our growing understanding of membrane transporters and their substrate specificity has
opened a new avenue in the field of targeted drug delivery. The L-type amino acid …
opened a new avenue in the field of targeted drug delivery. The L-type amino acid …
Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?
Relative to other neutral amino acid transporters, the expression levels of ASCT2 and LAT1,
are coordinately elevated in a wide spectrum of primary human cancers, suggesting that …
are coordinately elevated in a wide spectrum of primary human cancers, suggesting that …
Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in …
Many cancer cells depend on glutamine as they use the glutaminolysis pathway to generate
building blocks and energy for anabolic purposes. As a result, glutamine transporters are …
building blocks and energy for anabolic purposes. As a result, glutamine transporters are …
[HTML][HTML] Blood-brain barrier transport machineries and targeted therapy of brain diseases
An external file that holds a picture, illustration, etc. Object name is bi-6-225-g011. jpg
Introduction: Desired clinical outcome of pharmacotherapy of brain diseases largely …
Introduction: Desired clinical outcome of pharmacotherapy of brain diseases largely …